AMO Pharma is a privately held emerging biopharmaceutical company developing new treatments for serious and debilitating diseases including rare genetic disorders. Our goal is to identify and advance a robust pipeline of promising therapies for patient populations with significant areas of unmet need.

The company is led by seasoned industry professionals with extensive experience in all phases of asset acquisition and drug development and commercialization. The AMO Pharma portfolio currently includes clinical stage investigational drugs to treat neuromuscular or CNS symptoms of rare diseases. We will expand our portfolio with other promising therapies that represent important advances in medicine and patient care as well as strong commercial opportunities.

 

www.amo-pharma.com

 

 

CONTACTO:


 


 

 Coordinadora:

Ana Martínez (This email address is being protected from spambots. You need JavaScript enabled to view it.)

Gestora del Proyecto:

Nuria Mª Rivas (This email address is being protected from spambots. You need JavaScript enabled to view it.)

Centro de Investigaciones Biológicas (CIB-CSIC)

C/Ramiro de Maeztu, 9

28006 MADRID

 

 

 

 

 

 

             Proyecto ELA-MADRID.B2017/BMD-3813

 

 Proyecto financiado por la Comunidad de Madrid y la Unión Europea